MARKSANSMarksans Pharma Limited
Pharma · Drug Manufacturers - General · NSE · as of 2026-07-20 (delayed ~30 min in market hours)
₹266.95
▼ 0.06%Strong
Price & Volume
Loading chart…
Key Ratios
Market Cap (₹ cr)12,278.50
P/E29.42
P/B4.06
PEG1.12
ROE %15.16
ROCE %14.90
Debt / Equity0.11
EPS9.21
Revenue Growth %20.80
Profit Growth %63.50
Dividend Yield %0.29
Promoter Holding %43.87
FII Holding %18.60
DII Holding %—
Beta1.09
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
| Pullback to 21-EMA | LONG | 80% | ₹266.95 | ₹256.69 | ₹284.70 | 1.73 |
BUYConviction 81%
Why buy
- • Revenue growth: 20.8% YoY
- • Profit growth: 63.5% YoY
- • Debt/Equity: 0.11
- • RSI: 55
- • Price vs EMA21: above
- • Price vs SMA50: above
- • Pullback to 21-EMA signal (setup quality 80%)
Bull case
- • Revenue growth: 20.8% YoY
- • Profit growth: 63.5% YoY
- • Debt/Equity: 0.11
- • RSI: 55
Bear case
- • Dividend yield: 0.29%
- • MACD: bearish
- • Volume: 0.4x 20-day average
- • Volume trend: 0.6x baseline
Key risks
- • Dividend yield: 0.29%
- • MACD: bearish
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Entry (CMP)
₹266.95
Stop Loss
₹251.06
risk 6%
Target 1 (1.5R)
₹290.78
+8.9%
Target 2 (3R)
₹314.61
+17.9%
Support (20d)
₹253.60
Resistance (52w)
₹281.60
Risk : Reward
1 : 1.5 → 1 : 3
risking ₹15.89/share
ATR (volatility)
₹10.26
avg daily range
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹10.26). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.
Score Breakdown
Fundamental
78
Technical
66
Momentum
78
Risk (safety)
59